

Macroalgae-Derived Bioactive Molecules with Special Therapeutic Reference to Brain Disorders and Injury

Guest Editor:


Message from the Guest Editor

Deadline for manuscript
submissions:

closed (31 May 2020)

Bioactive natural products are promising for the development of novel therapeutic agents. Macroalgae, one of the largest marine inhabitants, are abundant in diverse molecules and are primarily synthesized to cope with various environmental stimuli. However, these bioactive compounds have been reported to possess numerous medicinal values, including neuroprotective, antioxidant, anti-inflammatory, and immunomodulatory properties. With the growing prevalence of oxidative stress- and inflammation-mediated brain disorders, including Alzheimer's, Parkinson's, and Huntington's diseases, natural product researchers and drug designers have been focusing their attention on the discovery and development of novel therapeutic leads from macroalgae-derived compounds or their skeleton. This Special Issue will cover the isolation and characterization of novel compounds from macroalgae, the bioactivity of already known molecules, the structure–activity relationship, and the mechanism of neuroprotection against various toxic insults representing *in vitro* and *in vivo* models of neurodegeneration and brain injury. Both original research and review papers are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)